Industry

When aiming for FDA approval, “fight” when you are right

Healio Optometry7h ago1 min read

WASHINGTON — When navigating the FDA approval process, ophthalmologists must be ready to “fight” on behalf of their findings, according to a speaker at SightLine.John P. Berdahl, MD, of Vance Thompson Vision told Healio that finding success with the FDA as a physician-entrepreneur requires a “clear, consistent and crystallized agreement on what the study is, and what the endpoints are.”{{VIDEO}}Berdahl also highlighted that it is the ophthalmologist’s responsibility to bring high quality data to the table. However, they must also be ready to advocate for the significance of their findings.

Read full article on Healio Optometry

AI Summary

Quick Take

Dr. John P. Berdahl advises physician-entrepreneurs to be prepared to vigorously advocate for their clinical findings and study significance during the FDA approval process. Success requires establishing a "crystallized agreement" on study design and endpoints early on, backed by high-quality data that the physician must be ready to defend.

Why It Matters

The path from clinical innovation to market availability is often hindered by regulatory friction, which can delay patient access to new technologies. For ophthalmologists involved in research and development, understanding that the FDA process involves active negotiation—not just passive submission—is crucial for navigating the complexities of clinical trial endpoints. This perspective shifts the role of the physician-entrepreneur from a data provider to a strategic advocate for the clinical relevance of their innovations.

Key Details

Physician-entrepreneurs must reach a clear and consistent agreement with the FDA regarding study design and primary endpoints before data collection begins.
Ophthalmologists bear the primary responsibility for bringing high-quality, rigorous data to the regulatory table.
Advocacy is essential when clinical findings are sound but require the physician to explain their real-world significance to regulators.
The advice was shared at the SightLine conference in Washington, highlighting the intersection of clinical practice and industry regulation.

Practice Implications

Clinicians involved in device or drug development should prioritize early and precise alignment with regulatory bodies on what constitutes a successful outcome. When data supports a clinical benefit that may be subject to interpretation, physicians should be prepared to defend the clinical utility of those results to ensure innovative tools successfully reach the market.

Who's Affected

OphthalmologistsPhysician-EntrepreneursClinical ResearchersIndustry ConsultantsR&D Executives

What's Next

As more ophthalmologists enter the entrepreneurial space, there is an increasing need for 'regulatory literacy' within the profession. Future industry discussions are likely to focus on strategies for negotiating trial endpoints that better reflect modern clinical success and patient outcomes.

AI-generated summary — always read the original source for full context

Discussion

No comments yet. Be the first to share your thoughts.